ArticleAddiction (Abingdon, England)2022
Duration of medication treatment for opioid-use disorder and risk of overdose among Medicaid enrollees in 11 states: a retrospective cohort study.
Article in Addiction (Abingdon, England), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 57 citations in OpenAlex.
- Reducing perceived barriers to scaling up overdose education and naloxone distribution and medications for opioid use disorder in the United States in the HEALing (Helping End Addiction Long-Term®) communities study.Preventive medicine · 2024Trial
- Discontinuation of medication treatment for opioid use disorder after a successful course: The discontinuation phase of the CTN-0100 (RDD) trial.Contemporary clinical trials · 2024Trial
- Continuity of Medications for Opioid Use Disorder in States With and Without Medicaid Prescription Cap Policies.Medical care · 2026Article
- The Behavioral Health Treatment Engagement and Retention Learning Collaborative to Improve Receipt and Continuity of Medication Treatment for Opioid Use Disorder.Substance use & addiction journal · 2026Article
- Association of Continuous Medicaid Eligibility With Postpartum Coverage and Opioid Use Disorder Treatment.American journal of preventive medicine · 2026Article
- Medications for opioid use disorder, recovery supports, and overdose risk -- a database linkage study of a rural cohort of people who inject drugs and use opioids.BMC public health · 2026Article
- Medicaid Prior Authorization and Discontinuation of Buprenorphine.Journal of addiction medicine · 2026Article
- Tailoring of a chronic pain self-management intervention for individuals with opioid use disorder in office-based addiction treatment.Journal of substance use and addiction treatment · 2026Article
- Too young for medication? prescriber perspectives on how age shapes medication for opioid use disorder prescribing in transition-age adults.Harm reduction journal · 2026Article
- Examining buprenorphine compared to methadone for likelihood of overdose during pregnancy, 2014-2021.Pregnancy (Hoboken, N.J.) · 2026Article
- Treatment of opioid use disorder in pregnancy among individuals with and without co-occurring stimulant use disorder: A retrospective cohort study.Journal of substance use and addiction treatment · 2026Article
- Health Plan Disenrollment and Mortality After Initiation of Medications for Opioid Use Disorder.JAMA psychiatry · 2026Article
- Cascade of Care for Opioid Use Disorder Among Medicaid Beneficiaries.JAMA network open · 2026Article
- Evaluating the optimal duration of medication treatment for opioid use disorder.Addiction (Abingdon, England) · 2026Article
- Longitudinal Patterns of Dental Health Care Utilization 18 Months Before and 36 Months After Initiation of Index Medications for Opioid Use Disorder.Journal of addiction medicine · 2026Article
- Retention among Medicaid beneficiaries in opioid treatment programs in California.Journal of substance use and addiction treatment · 2026Article
- Medication for Opioid Use Disorder and Perioperative Outcomes for Benign Hysterectomy.O&G open · 2026Article
- Distributed fusion R-learner of heterogeneous treatment effect using distributed medicaid data.Biometrics · 2026Article
- Policies and practices addressing medication and substance use in recovery housing: findings from a nationally representative survey.The American journal of drug and alcohol abuse · 2026Article
- Buprenorphine Treatment Duration and Adherence Among Youth and Subsequent Health Outcomes.Pediatrics · 2025Article
Corrections and comments
- Commented on by
Authors and funding
16 authors at 11 institutions in 2 countries.
Funding
Abstract
BACKGROUND AND
aimsMedication for opioid use disorder (MOUD) reduces harms associated with opioid use disorder (OUD), including risk of overdose. Understanding how variation in MOUD duration influences overdose risk is important as health-care payers increasingly remove barriers to treatment continuation (e.g. prior authorization). This study measured the association between MOUD continuation, relative to discontinuation, and opioid-related overdose among Medicaid beneficiaries.
designRetrospective cohort study using landmark survival analysis. We estimated the association between treatment continuation and overdose risk at 5 points after the index, or first, MOUD claim. Censoring events included death and disenrollment. SETTING AND
participantsMedicaid programs in 11 US states: Delaware, Kentucky, Maryland, Maine, Michigan, North Carolina, Ohio, Pennsylvania, Virginia, West Virginia and Wisconsin. A total of 293 180 Medicaid beneficiaries aged 18-64 years with a diagnosis of OUD and had a first MOUD claim between 2016 and 2017. MEASUREMENTS: MOUD formulations included methadone, buprenorphine and naltrexone. We measured medically treated opioid-related overdose within claims within 12 months of the index MOUD claim.
findingsResults were consistent across states. In pooled results, 5.1% of beneficiaries had an overdose, and 67% discontinued MOUD before an overdose or censoring event within 12 months. Beneficiaries who continued MOUD beyond 60 days had a lower relative overdose hazard ratio (HR) compared with those who discontinued by day 60 [HR = 0.39; 95% confidence interval (CI) = 0.36-0.42; P < 0.0001]. MOUD continuation was associated with lower overdose risk at 120 days (HR = 0.34; 95% CI = 0.31-0.37; P < 0.0001), 180 days (HR = 0.31; 95% CI = 0.29-0.34; P < 0.0001), 240 days (HR = 0.29; 95% CI = 0.26-0.31; P < 0.0001) and 300 days (HR = 0.28; 95% CI = 0.24-0.32; P < 0.0001). The hazard of overdose was 10% lower with each additional 60 days of MOUD (95% CI = 0.88-0.92; P < 0.0001).
conclusionsContinuation of medication for opioid use disorder (MOUD) in US Medicaid beneficiaries was associated with a substantial reduction in overdose risk up to 12 months after the first claim for MOUD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.